TIAA CREF Investment Management LLC decreased its stake in shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) by 2.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 45,059 shares of the specialty pharmaceutical company’s stock after selling 935 shares during the quarter. TIAA CREF Investment Management LLC owned about 0.20% of Adamas Pharmaceuticals worth $788,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in ADMS. Vanguard Group Inc. increased its holdings in shares of Adamas Pharmaceuticals by 10.3% in the 1st quarter. Vanguard Group Inc. now owns 716,419 shares of the specialty pharmaceutical company’s stock worth $12,537,000 after purchasing an additional 66,825 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Adamas Pharmaceuticals by 212.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 60,897 shares of the specialty pharmaceutical company’s stock worth $1,066,000 after purchasing an additional 41,436 shares in the last quarter. Emerald Advisers Inc. PA increased its holdings in shares of Adamas Pharmaceuticals by 2.7% in the 2nd quarter. Emerald Advisers Inc. PA now owns 532,727 shares of the specialty pharmaceutical company’s stock worth $9,317,000 after purchasing an additional 14,042 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Adamas Pharmaceuticals by 4.9% in the 1st quarter. Geode Capital Management LLC now owns 125,793 shares of the specialty pharmaceutical company’s stock worth $2,201,000 after purchasing an additional 5,920 shares in the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of Adamas Pharmaceuticals by 28.4% in the 1st quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock worth $266,000 after purchasing an additional 3,358 shares in the last quarter. Institutional investors and hedge funds own 70.61% of the company’s stock.

Shares of Adamas Pharmaceuticals, Inc. (NASDAQ ADMS) opened at $28.79 on Tuesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.32 and a current ratio of 8.35. Adamas Pharmaceuticals, Inc. has a fifty-two week low of $13.50 and a fifty-two week high of $29.29.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.01) by ($0.03). During the same quarter last year, the company earned ($0.66) earnings per share. The company’s quarterly revenue was down 99.3% compared to the same quarter last year. equities research analysts anticipate that Adamas Pharmaceuticals, Inc. will post -3.87 EPS for the current fiscal year.

A number of analysts have commented on ADMS shares. Evercore ISI started coverage on Adamas Pharmaceuticals in a report on Monday, October 30th. They issued an “outperform” rating for the company. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $30.00 price objective on shares of Adamas Pharmaceuticals in a report on Friday, September 1st. They noted that the move was a valuation call. Zacks Investment Research raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th. BidaskClub lowered Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 19th. Finally, ValuEngine lowered Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, October 13th. Two analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $42.00.

COPYRIGHT VIOLATION WARNING: “TIAA CREF Investment Management LLC Sells 935 Shares of Adamas Pharmaceuticals, Inc. (ADMS)” was published by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/tiaa-cref-investment-management-llc-sells-935-shares-of-adamas-pharmaceuticals-inc-adms/1701671.html.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Want to see what other hedge funds are holding ADMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS).

Institutional Ownership by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.